pharmazz

  • Marketing authorization received for Lyfaquinâ„¢ (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency

    May 14, 2020, - WILLOWBROOK, Ill., May 14, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it has received marketing authorization of centhaquine, a first-in-class drug, to manage patients with hypovolemic shock from the Indian regulatory agency. Centhaquine is likely to be a transformational therapy for hypovolemic shock because it ameliorates key drivers of mortality.....
    Read More
  • Sovateltide significantly (p=0.0157) improved clinical outcome (modified Rankin Scale) in patients with acute cerebral ischemic stroke when compared to standard of care

    Apr 27, 2020, - WILLOWBROOK, Ill., April 27, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that sovateltide, an endothelin-B receptor agonist, significantly (p=0.0157; two-tailed unpaired t-test; t=2.476; df=70) improved modified Rankin Scale (mRS) of acute cerebral ischemic stroke patients when compared to patients receiving the best standard of care. These results are based on an interim 30-day analysis of multicentric, randomized, blinded, controlled efficacy clinical trials (NCT04046484; NCT04047563) in acute ischemic stroke patients. ....
    Read More
  • Centhaquine can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, acute respiratory distress syndrome (ARDS), multiple organ dysfunction score (MODS) and mortality in coronavirus disease 2019 (COVID-19) patients

    Apr 09, 2020, - WILLOWBROOK, Ill., April 9, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that centhaquine, a drug in final stage of development, can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome (ARDS), reduce multiple organ dysfunction score (MODS) and decrease mortality in patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).,...
    Read More
  • Dosing of first patient in phase 3 pivotal study of sovateltide (PMZ-1620), a first-in-class investigational product, for acute cerebral ischemic stroke

    Nov. 23, 2019, - WILLOWBROOK, Ill., Nov. 23, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced the initiation of dosing in its pivotal, phase 3 clinical trial evaluating sovateltide for the treatment of acute cerebral ischemic stroke...
    Read More
  • Pharmazz submits application for marketing authorization of centhaquine (PMZ-2010), a first-in-class investigational product, for patients with hypovolemic shock

    Oct. 28, 2019, - WILLOWBROOK, Ill., Oct. 28, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it successfully submitted Application for Marketing Authorization of centhaquine to the Central Drugs Standard Control Organization (CDSCO)...
    Read More
  • Sovateltide (PMZ-1620), an Endothelin-B receptor Agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics

    Sept. 30, 2019, - WILLOWBROOK, Ill., Sept. 30, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it made 5 presentations at the Sixteenth International Conference on Endothelin held in Kobe...
    Read More
  • PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke

    July 18, 2019, - WILLOWBROOK, Ill., July 18, 2019 /PRNewswire/ -- Pharmazz, Inc., today announced that it has received permission to initiate a prospective, multicentric, randomized, double-blind, parallel, phase III clinical study to assess efficacy of PMZ-1620 along with standard treatment in patients of acute ischemic stroke in India...
    Read More
  • Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019

    Feb. 07, 2019, - NAPERVILLE, Ill., Feb. 7, 2019 /PRNewswire/ -- Pharmazz, Inc., today announced that data from the Phase 2 clinical study in patients with acute cerebral ischemic stroke, were presented in the late breaking Multicenter, Ongoing Clinical Trials Posters II (Board CTP27) session at the International Stroke Conference 2019 in Honolulu, Hawaii February 6-8, 2019...
    Read More
  • Phase 2 Results on Efficacy of PMZ-2010 (Centhaquin) in Patients with Hypovolemic Shock Presented at AHA Scientific Sessions 2018

    Nov. 12, 2018, - NAPERVILLE, Ill., Nov. 12, 2018 /PRNewswire/ -- Pharmazz, Inc., today announced that data from the Phase 2 clinical study in patients with hypovolemic shock, were presented in the Drug Discovery-Heart Failure Oral Abstracts Session II at the American Heart Association Scientific Sessions in Chicago November 12, 2018.
    Read More
  • Clinical phase II results indicate that PMZ-2010 (centhaquin) is a novel highly effective resuscitative agent for hypovolemic shock

    May 17, 2018, - NAPERVILLE, Ill., May 17, 2018 /PRNewswire/ - Pharmazz, Inc. is pleased to announce interim analysis of a prospective, multi-centric, randomized, double-blind, parallel, saline controlled phase II study of PMZ-2010 (centhaquin) ...
    Read More
  • Notice of allowance issued for two Canadian patent applications and US Congressman Bill Foster visits Midwestern University

    March 30, 2018, - NAPERVILLE, Ill., March 30, 2018 /PRNewswire/ - Pharmazz, Inc. is pleased to announce that Notice of Allowance has been issued for Canadian Patent Application No. 2696398 titled "Methods for treatment of stroke or cerebrovascular accidents using an ET-B receptor agonist." PMZ-1620, a selective endothelin-B receptor agonist, is in clinical phase II trials in patients suffering from cerebral ischemia (stroke) and mild to moderate Alzheimer's disease...
    Read More
  • Issuance of patent and initiation of a study to evaluate PMZ-1620 in dogs with degenerative myelopathy, a disease similar to human amyotrophic lateral sclerosis (ALS)

    Jan. 11, 2018, - NAPERVILLE, Ill., Jan. 11, 2018 /PRNewswire/ - Pharmazz, Inc. is pleased to announce that Indian Patent No. 290038 on a pharmaceutical composition comprising IRL-1620 (PMZ-1620) was granted on November 28, 2017. PMZ-1620, a selective endothelin-B receptor agonist, is presently undergoing clinical studies in patients suffering from mild to moderate Alzheimer's disease. In addition, a phase II study, using PMZ-1620, is being conducted in patients with cerebral ischemic stroke...
    Read More
  • Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management

    Oct. 18, 2017, - NAPERVILLE, Ill., Oct. 18, 2017 /PRNewswire/ - Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management. Inadequate pain control is a major public health concern in the USA. Dr. Anil Gulati and his colleagues have been working on this technology since 2002, and have conducted extensive studies and demonstrated that endothelin-A receptor antagonists such as PMZ-2123 potentiate analgesic effects of morphine and oxycodone and eliminates tolerance to these drugs...
    Read More
  • Pharmazz, Inc. initiates human phase II studies of PMZ-2010 for the treatment of hemorrhagic shock and presents data at the Society of Critical Care Medicine Annual Meeting

    Feb 3, 2017 - NAPERVILLE, Ill., Feb. 3, 2017 /PRNewswire/ -- Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. The company has initiated a human phase II study in India to determine the efficacy of PMZ-2010 (centhaquin) in patients of hypovolemic shock....
    Read More
  • Pharmazz, Inc. advances its product pipeline for the treatment of stroke, strengthens patent portfolio and presents hemorrhagic shock data at the American Heart Association

    Nov 30, 2016 - NAPERVILLE, Ill., Nov. 30, 2016 /PRNewswire/ - Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. Results of the human safety and pharmacokinetics of PMZ-2010 were presented at the American Heart Association Scientific Sessions 2016...
    Read More
  • Pharmazz, Inc. strengthens its patent portfolio with Notice of Issuance for PMZ-2123 (BQ123) in the treatment of diabetic ketoacidosis

    Apr 22, 2016 - NAPERVILLE, Ill., April 22, 2016 /PRNewswire/ - Pharmazz, Inc. ... This press releasecontains "forward-looking statements" within the ...
    Read More